

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: 2013-05-16 | Period of Report: 2013-05-16  
SEC Accession No. 0000950103-13-003064

(HTML Version on [secdatabase.com](http://secdatabase.com))

FILER

**Shire plc**

CIK: **936402** | IRS No.: **000000000** | Fiscal Year End: **1231**  
Type: **8-K** | Act: **34** | File No.: **000-29630** | Film No.: **13849461**  
SIC: **2834** Pharmaceutical preparations

Mailing Address	Business Address
HAMPSHIRE INTL BUSINESS PARK	HAMPSHIRE INTL BUSINESS PARK
CHINEHAM BASINGSTOKE HAMPSHIRE ENGLAND RG X0 R924 8EP	CHINEHAM BASINGSTOKE HAMPSHIRE ENGLAND RG X0 R924 8EP 441256894000

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 16, 2013

**Shire plc**

---

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands

---

(State or other jurisdiction of incorporation)

0-29630  
(Commission File Number)

98-0601486  
(IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin  
24, Republic of Ireland

---

(Address of principal executive offices)

(Zip code)

Registrant's telephone number, including area code

+353 1 429 7700

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

Shire plc has issued the press release attached hereto as Exhibit 99.01 which is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibit is filed herewith:

99.01 Press Release dated May 16, 2013

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC

By: /s/ T May

Name: Tatjana May

Title: General Counsel

Dated: May 16, 2013

---

## EXHIBIT INDEX

Number	Description
99.01	Press release dated May 16, 2013

---

# Press Release

[www.shire.com](http://www.shire.com)



## Transaction in Own Shares

May 16, 2013 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that, in accordance with the authority granted by shareholders at the Company’s Annual General Meeting on April 30, 2013, it purchased 45,690 of its ordinary shares of 5 pence each (“Ordinary Shares”) on May 15, 2013 through both direct purchases of Ordinary Shares, and through the purchase of Ordinary Shares underlying ADRs. The highest and lowest price paid for the directly acquired Ordinary Shares was 2063.00 pence per share and 2039.00 pence per share respectively, and for those Ordinary Shares acquired through the purchase of ADRs was 3105.67 cents per share and 3082.00 cents per share respectively.

The purchased shares will be held as treasury shares. Following the above purchase, the Company holds 8,678,195 Ordinary Shares as treasury shares and has 554,154,198 Ordinary Shares in issue (excluding treasury shares).

The purchases were made by an independent third party which makes its trading decisions independently of, and uninfluenced by, the Company. The independence of the third party enables the Company to continue to purchase Ordinary Shares (including Ordinary Shares underlying ADRs) during close periods and other prohibited periods, should they arise. The third party has been appointed by the Company to make purchases to December 31, 2013.

### For further information please contact:

#### Investor Relations

Eric Rojas

[erojas@shire.com](mailto:erojas@shire.com)

+1 781 482 0999

Sarah Elton-Farr

[seltonfarr@shire.com](mailto:seltonfarr@shire.com)

+44 1256 894157

### NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

[www.shire.com](http://www.shire.com)

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX